Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
OCD
Biotech
Welcome to new (Bio) Haven: CEO hopes to strike gold twice
After selling its potential blockbuster migraine program to Pfizer for $11.6 billion, Biohaven embarks on a new journey, hoping to strike gold twice.
Max Bayer
May 11, 2022 11:11am
Biohaven fails OCD trial but pushes on to phase 3
Jun 24, 2020 8:14am
FDA clears first magnetic, noninvasive device treatment for OCD
Aug 20, 2018 9:27am
